A revenue of USD 1.1 billion is forecast for the Internal Radiation Therapy Market by 2024. It is projected that the market will expand at a 6.2% CAGR between 2024 and 2034. The internal radiation therapy market size is expected to reach USD 2 billion by 2034.
Advanced imaging techniques such as ultrasound, power Doppler imaging, positron emission tomography, and magnetic resonance imaging have radically expanded the scope of internal radiation therapy. While minimizing harm to surrounding healthy tissues, these imaging technologies allow for a more precise focus on tumors.
Cancer care is increasingly being delivered and monitored using digital science, analytics, and telemedicine. Healthcare IT advancements enable better, more personalized treatment planning, remote patient monitoring, and more efficient coordination of cancer care.
Global Internal Radiation Therapy Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 1 billion |
| Estimated Size, 2024 | USD 1.1 billion |
| Projected Size, 2034 | USD 2 billion |
| Value-based CAGR (2024 to 2034) | 6.2% |
A new generation of brachytherapy algorithms that account for tissue heterogeneity and applicator materials are being developed. In comparison to standard TG-43 formalism, these algorithms illustrate the brought dose more accurately. Adaptive and actual-time planning in brachytherapy has been made possible by the development of advanced dose-optimizing tools. Harmonizing and expediting the planning process allows for a more customized and responsive approach to treatment.
With the OncoSmart catheter gadget, a single implant can cover multiple treatment fractions, allowing patients to maintain a normal existence between treatments. With the Breast CT/MR template set, multicatheter implants can be guided smoothly and comfortably to reduce patient discomfort.
Radiation therapy performed internally can often provide an entire radiation dose in fewer treatments, either as a single treatment or in several smaller doses. The patients may find this to be more convenient, and the length of their treatments may be shortened.
An effective treatment course may include internal radiation therapy along with external radiation therapy. The combination of radiation therapy and chemotherapy might be more effective.
CT, PET, and MRI imaging techniques are used in image-guided radiation therapy (IGRT) to allow more accurate tumor targeting and dose delivery. Re-planning IGRT is a possibility at some point in the treatment path to accommodate changes in the length of the tumor.
In comparison with photon-based radiotherapy, particle therapy, including proton beam therapy, could deliver radiation with even higher precision, potentially lowering side effects.
Techniques such as X-ray activated photodynamic therapy (XPDT) the usage of biocompatible yttrium oxide scintillator-photosensitizer complexes to generate cytotoxic reactive oxygen species, and azido-derivatives of 2-deoxy-D-glucose (2-DG) as agents of radiation-triggered DNA damage.
Collaborations between educational establishments, research groups, and agency stakeholders help achieve brachytherapy generation and increase its scientific applications. In the end, these partnerships enhance treatment effects and patient satisfaction by improving radioisotope development, shipping methods, and patient care methods.
By increasing patient awareness and education, brachytherapy can be made more accessible to patients. Healthcare providers and patients can be educated about the advantages and safety of brachytherapy to promote its adoption and enable early cancer detection.
To integrate brachytherapy into complete cancer care applications worldwide, patient advocacy groups and professional societies play an essential role.
Here is a table illustrating the predicted CAGR for internal radiation therapy from 2024 through 2034. The first half (H1) of the decade is projected to have a 7% growth rate, followed by a 6.7% growth rate in the second half.
| Particular | Value CAGR |
|---|---|
| H1 | 7% (2023 to 2033) |
| H2 | 6.7% (2023 to 2033) |
| H1 | 6.2% (2024 to 2034) |
| H2 | 5.8% (2024 to 2034) |
The first half of 2024 is projected to have a CAGR of 6.2%, and the second half of 2034 will have a CAGR of 5.8%.
Awareness and Guidelines for Internal Radiation Treatment Market to Fuel Growth
As an oncology and other clinical field treatment modality, internal radiation therapy is being increasingly adopted. Technology, demographics, healthcare policies, and evolving patient options are all important factors shaping brachytherapy's future.
Radiation delivery systems, imaging systems, and remedy planning technologies are all driving innovation in brachytherapy. With improved radioisotope and radiation source technology, treatment techniques can be more customizable and patient-specific, thereby optimizing healing.
Brachytherapy adoption is also driven by healthcare guidelines and reimbursement frameworks. The reimbursement incentives in healthcare encourage companies to incorporate brachytherapy into comprehensive cancer care programs.
Clinical and patient confidence is bolstered by regulatory support for brachytherapy in private healthcare settings.
Increasing demand for less invasive treatments that minimize disruptions to daily life and healing periods fuels brachytherapy demand. For patients seeking customized and effective cancer treatments, brachytherapy offers a more targeted technique with fewer side effects than conventional surgery or radiation.
Opportunity for Internal Radiation Therapy
As technology advances, internal radiation therapy can become more precise and effective. Personalized and focused therapies are becoming more common as new imaging technology, software planning treatments, and radiation transport systems are developed.
AI and device learning algorithms can optimize brachytherapy plans based on patient-specific facts, maximizing therapeutic advantages while minimizing side effects.
Globally, the incidence of cancer is increasing, creating a growing market opportunity for radiation treatment inside the body. As the incidence of cancer continues to rise, particularly in older populations, effective and cost-effective treatment alternatives like brachytherapy may be necessary.
Guidelines and reimbursement frameworks encouraging minimally invasive and outpatient treatments also promote brachytherapy as an alternative treatment option.
Investing in radiation therapy provides massive opportunities to grow, innovate, and expand its role in cancer treatment and beyond. A huge opportunity lies in diversifying cancer treatments beyond traditional cancer treatments.
Many non-cancerous situations are being treated with brachytherapy, including cardiovascular disease, ophthalmological disorders, and benign tumors. The increasing use of brachytherapy gadgets and technologies does not only impact the market for brachytherapy but also improves medical research and care.
Internal Radiation Therapy Trends
Treatment planning and delivery strategies are increasingly incorporating advanced imaging technology. CT scans and MRIs are increasingly used to locate tumors exactly and guide radiation assets, improving the accuracy and effectiveness of treatment.
The trend towards photograph-guided brachytherapy has not only improved outcomes but also reduced the risk of unfavorable consequences on surrounding healthy tissue.
As radiation treatment progresses, minimally invasive methods are becoming more popular. The goal of minimally invasive brachytherapy is to deliver radiation assets directly into or near tumors, minimizing trauma and reducing recovery times.
This method is especially effective for cancers in hard-to-reach regions where surgical removal may be difficult. A revolution in the delivery of radiation therapy and a change in the structure of the treatment vessel are driving advancements in brachytherapy.
To target tumors more precisely and minimize radiation exposure to healthy tissues, new radioisotopes with advantageous emission properties are being developed. As software and hardware innovations streamline treatment planning, brachytherapy has become more powerful and accessible to hospitals and patients.
A wide range of symptoms can be treated with brachytherapy, from prostate cancer to cervical cancer. Breast, skin, head, and neck cancers are among the malignancies that can be treated using inner radiation therapy.
Clinical studies demonstrate that brachytherapy is both effective and safe in a variety of oncological circumstances, supporting this broader application.
Cost and Regulations Could Limit Internal Radiation Therapy Industry
The excessive initial setup costs for gadgets, infrastructure, and training will hamper the market. Brachytherapy is a highly specialized treatment requiring highly-priced radiation equipment, treatment planning structures, and fine quality assurance measures.
To perform brachytherapy techniques correctly and successfully, healthcare carriers need extensive training and certification, in addition to their high value and complexity. The radiation therapy market also faces numerous regulatory compliance and safety requirements.
To minimize radiation publicity risks for patients and healthcare staff, brachytherapy requires adherence to stringent regulatory guidelines.
Treatment planning and shipping are further complicated by patient anatomy and tumor characteristics, requiring customized processes. The possibility that surrounding healthy tissues could be damaged is also a concern.
Even though brachytherapy aims to deliver precise radiation doses, there will always be a risk of radiation-induced damage to nearby organs or tissues. While optimizing treatment efficacy, managing these aspects' consequences remains a medical mission.
To ensure brachytherapy results that are steady and impeccable, interdisciplinary coordination and complex remedy planning must be combined.
A customized treatment plan can be designed for each patient, involving radiologists, clinical physicists, and other doctors. To ensure top-quality treatment outcomes and patient satisfaction, these disciplines and technology must be seamlessly integrated.
A CAGR of 5.5% was recorded for internal radiation therapy between 2019 and 2023. According to estimates, the internal radiation therapy industry generated USD 1 billion in 2023, in contrast to USD 783.6 billion in 2019.
Several imaging techniques, including those that can be used in real-time, have significantly expanded the range of options for radiation treatment inside the body.
Radiation oncology advances, such as Stereotactic Body Radiation Therapy (SBRT), contribute to the growth of radiation treatment within the body. By increasing radiation doses during SBRT, most cancers are likely to be treated more effectively while toxicity and treatment time are reduced.
It has been demonstrated that SBRT can successfully control tumors in level 1 lung cancer patients ineligible for surgery with a 98% success rate.
The use of 3-D Conformal Radiotherapy and Intensity Modulated Radiation Therapy, along with internal radiation therapy, allows more accurate targeting of tumors while sparing wholesome tissues. These strategies are predicted to continue to improve cancer patients' survival and side impact profiles as they undergo radiation therapy.
Automatic dose optimization techniques such as IPSA (Inverse Planning Simulated Annealing) and HIPO (Hybrid Inverse Treatment Planning Optimization) improve plan quality by reducing stay variations and controlling highs and lows during treatment.
A study conducted by the National Library of Medicine suggests that not completing treatment on time may negatively impact a patient's oncologic prognosis for gynecologic malignancies. Oncologic outcomes may be affected by delays in prostate or breast cancer treatment.
In case of a delay in radiation therapy administration, hormone therapy may be an acceptable temporizing approach. By shortening fractionation regimens of IRT, patients will be exposed to less radiation and resources will be saved.
Most of the global market is dominated by Tier 1 companies, accounting for 45.7% share. Tier 1 companies are usually leaders in the industry and are known for their innovative products, industry influence, and global reach.
Providing comprehensive integrated cancer care solutions around the world, they are a global leader in cancer care. Tier 1 players focus on precision medicine and aim to achieve better outcomes for patients. A few notable companies in Tier 1 include Varian Medical Systems, Inc., and Elekta AB.
With a share of 26.2%, Tier 2 players offer cancer treatment in niche areas. A majority of Tier 2 players are mid-size companies that specialize in specific aspects of cancer care. Their primary focus is on the development of innovative treatments and technologies targeted at cancer patients.
A Tier 2 company generally offers specialized products or services and plays an important role in a specific segment of the brachytherapy industry. The focus on quality and safety is one of the key aspects of seed production and distribution. Tier 2 companies include Eckert & Ziegler BEBIG, IsoRay Medical, Inc., and Theragenics Corporation.
Tier 3 companies typically cater to niche markets within the brachytherapy market through their narrow focus, local presence, or product/service specialization. In Tier 3, the companies' contributions are significant, but they provide secondary support more than primary technology development.
Tier 3 companies play a more specialized and supportive role in maintaining treatment standards within the brachytherapy ecosystem. Players include Becton, Dickinson and Company (BD), CIVCO Medical Solutions, Sun Nuclear Corporation, ICAD, Inc., Median Technologies, and Symphony AI.
The effectiveness of various internal radiation therapies is assessed in different countries. The use of radiation treatment for the treatment of cancer is widespread in more than 50 countries. Cancer cells are targeted using this technique, which minimizes damage to healthy cells.
Treatment with this method is particularly effective if the cancer is resistant to other treatments. The CAGR of 10.4% for India in Asia Pacific is expected to remain the most significant by 2034. A 5% CAGR is predicted for Canada by 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| The United States | 2.9% |
| Canada | 5% |
| The United Kingdom | 3.3% |
| Germany | 2.9% |
| India | 10.4% |
| China | 9.2% |
| South Korea | 7.3% |
The number of cancer cases in Canada has been steadily increasing, and brachytherapy is increasingly used to treat cervical, prostate, and breast cancer. The Canadian Cancer Society says cancer remains the nation's leading cause of death, emphasizing the need for innovative medical treatments.
As part of Canada's publicly funded healthcare system, patients have access to high-quality cancer treatments, such as internal radiation treatments. Similar to government funding for cancer care, brachytherapy is also available and widely used by the government.
The number of cancer care facilities providing radiation therapy in Canada is about 44. Calgary, Edmonton, Red Deer, Lethbridge, and Medicine Hat are some of the centers where radiation therapists work for Alberta Health Services - Cancer Care Alberta.
It is expected that cancer incidence will increase by 83% from 2012 to 2042 in Canada. The rise in deaths related to prostate, breast, lung, and colorectal cancer will account for over 50% of the increase.
Significant growth is expected in the United Kingdom over the next several years. A CAGR of 3.3% is forecast for the industry during the forecast period.
Radiation therapy within the body, including systemic radiation therapy, is expected to be affected by cancer incidence and metastasis. Increasingly, the incidence of cancer is increasing with age in the United Kingdom, which makes radiation therapy more necessary.
A multi-pronged radiation therapy solution may have evolved due to technological advancements in the field, especially endogenous radiation therapy. To achieve accuracy and patient-centered care, these developments aim to develop medicine.
The United Kingdom's researchers and clinicians are making significant contributions to the refinement and validation of endogenous radiation therapy. Continual improvements in treatment outcomes and benefits are supported by this research environment.
In the United Kingdom, several leading cancer treatment centers offer state-of-the-art brachytherapy services, such as The Royal Marsden Hospital in London. These centers play a critical role in increasing systemic radiation therapies.
India is experiencing positive growth in the field of internal radiotherapy. An expansion of 10.4% is projected in India's industry between 2024 and 2034. In India, both public and private cancer treatment centers have been equipped with brachytherapy facilities. According to the World Health Organization (WHO), India is expected to have two million cancer cases by 2040, and one million cancer deaths.
Approximately 2.5 million women were affected by breast cancer in 2020, resulting in 690,000 deaths worldwide. As cancer rates rise, internal radiation therapy has become more popular. Several strategies have been deployed to bridge the gap in access to radiation therapy in India, including establishing rural cancer care centers.
The expansion of the private sector's capabilities and the implementation of financial assistance programs through national insurance schemes. By continuing these efforts, more patients will be able to receive treatment for their illnesses.
Information about the leading segments of the industry is provided in the following section. The breast cancer segment accounted for 38.7% of the value share in 2023. Based on the dosage, HDR internal radiation therapy had a market share of 69.7% in 2023.
| Therapeutic Applications | Breast Cancer |
|---|---|
| Value Share (2024) | 38.7% |
The use of IRT after breast preservation surgery (lumpectomy) is common for treating early-stage breast cancers. Radiation implants can be implanted surgically in the areas where tumors have been removed, making the procedure simpler. By providing high doses of radiation simultaneously to the tumor site, the radiation exposure to healthy tissue is minimized.
Breast cancer patients most often receive intracavitary radiation therapy as part of their treatment. An implant containing radioactive substances is implanted inside the patient and remains in place until treatment has been completed.
Increasing government awareness of minimally invasive surgeries and technological advancements have contributed to the market's growth.
Patients with breast cancer who receive IRT can benefit from the same degree of safety and effectiveness as those who receive external beam radiation therapy (EBRT). Recent clinical trials found that intensive IRT for three weeks was as effective as EBRT for four to six weeks, with similar recurrence rates and outcomes.
| Dosage | HDR Internal Radiation Therapy |
|---|---|
| Value Share (2024) | 69.7% |
By using this method, radiation can be transported more concentrated and specifically to the tumor while minimizing exposure to healthy tissues. By supplying radiation directly to the tumor, HDR brachytherapy produces minimal collateral damage to healthy tissues around the tumor.
In comparison with low-dose-price (LDR) brachytherapy, excessive dose rates allow for shorter treatment times. A large number of HDR treatments can be performed outpatiently, reducing the need for clinic visits.
Depending on the size, shape, and location of the tumor, the treatment can be tailored. HDR brachytherapy can be performed on an outpatient basis, resulting in fewer hospital stays and faster returns home for patients.
The fact that HDR brachytherapy restricts radiation exposure to healthful tissues reduces the risks and complications associated with external beam radiation therapy (EBRT). Imaging techniques are often used to locate the applicators used to deliver the radiation, ensuring accuracy and minimizing pain.
Compared to more invasive surgical options, HDR brachytherapy facilitates faster recovery times for patients due to its minimally invasive nature and outpatient basis. A focus on and far-off afterloading strategy in HDR brachytherapy reduces radiation exposure to the patient and healthcare providers.
Collaborating with universities and research institutions can help companies stay competitive. Joint research initiatives can contribute to the development of new technologies and treatments. The adoption of their products can be increased by forming alliances with hospitals and cancer treatment centers.
Recent Developments
Based on product type, the segment includes seeds, applicators and afterloaders, and electronic internal radiation therapy.
Based on dosage type, the segments are classified into HDR internal radiation therapy and LDR internal radiation therapy.
In terms of application, the sector includes prostate cancer, gynecological cancer, breast cancer, and other applications.
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia, East Asia, the Middle East, and Africa have been covered in the report.
A 6.2% CAGR is predicted between 2024 and 2034 for the internal radiation therapy market.
It is estimated that the market for internal radiation therapy will reach USD 1.1 billion in 2024.
By 2034, the market for internal radiation therapy is projected to reach USD 2 billion.
HDR internal radiation therapy accounted for 69.7% of the market in 2023.
The key players in the internal radiation therapy industry include Eckert & ZieglerVarian Medical Systems, Inc., IsoRay Medical, Inc., Elekta AB, and Theragenics Corporation.
Explore Similar Insights
Internal Radiation Therapy Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
